Market research
3759.HK Pharmaron Beijing Co., Ltd
HK HKD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 61B
- P/E ratio
- 29.91
- Analyst target
- 38.1029
- Dividend yield
- 0.6%
- Beta
- 0.62
Profile
Company facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CNE100003PG4
- Market cap
- 61B
- P/E ratio
- 29.91
- Analyst target
- 38.1029
- Dividend yield
- 0.6%
- Beta
- 0.62
About
About Pharmaron Beijing Co., Ltd
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 3759.HK discussion.
5 years, 5 months ago
Pharmaron Beijing Co., Ltd is currently in a long term uptrend where the price is trading 34.1% above its 200 day moving average.
From a valuation standpoint, the stock is 82.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.6.
Pharmaron Beijing Co., Ltd's total revenue sank by 27.0% to $2B since the same quarter in the previous year.
Its net income has dropped by 0.7% to $383M since the same quarter in the previous year.
Finally, its free cash flow grew by 94.5% to $-19M since the same quarter in the previous year.
Based on the above factors, Pharmaron Beijing Co., Ltd gets an overall score of 3/5.